- IsoRay’s proprietary Cesium-131 based therapies have cost, effectiveness and side effect advantages, which are leading to increased application.
- It is still in the early innings of capturing an increasing market.
- Besides brachytherapy for prostate cancer, which is the main usage today, the seeds can be used against other cancers, and the company has no international sales yet.
- We believe the shares have further to run, but keep an eye on cash levels.
IsoRay Is Set For Further Growth
February 23rd, 2020 · No Comments